A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Malignant Pleural Mesothelioma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2017
At a glance
- Drugs Gemcitabine (Primary) ; Imatinib (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 09 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 20 Jul 2016 Planned End Date changed from 1 Nov 2018 to 1 Dec 2016.